Related Experiment Video
Updated: Feb 23, 2026

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
Published on: April 18, 2025
Hemorheological dysfunction in cardiac syndrome X
Emine Kilic-Toprak1, Olga Yaylali2, Yalin Tolga Yaylali3
1a Faculty of Medicine, Department of Physiology , Pamukkale University , Kinikli , Denizli, Turkey.
Insights
Cardiac Syndrome X (CSX) patients exhibit impaired blood flow properties. This study found reduced erythrocyte deformability and increased erythrocyte aggregation and plasma viscosity in CSX patients, suggesting hemorheological factors contribute to the condition.
Area of Science:
- Cardiology
- Hematology
- Biophysics
Background:
- Cardiac Syndrome X (CSX) presents as angina with normal coronary arteries, but its underlying causes remain unclear.
- Investigating blood rheology, including erythrocyte aggregation, deformability, and plasma viscosity, is crucial for understanding CSX pathophysiology.
Purpose of the Study:
- To investigate alterations in blood rheology in patients diagnosed with Cardiac Syndrome X.
- To determine the relationship between hemorheological parameters and the risk of developing CSX.
Main Methods:
- Compared blood rheology (erythrocyte aggregation, deformability, plasma viscosity) in 26 CSX patients and 37 healthy controls.
- Utilized ektacytometry for erythrocyte measurements and rotational viscometry for plasma viscosity.
Main Results:
- CSX patients showed significantly lower erythrocyte deformability at 1.69 and 3.00 Pa.
- Erythrocyte aggregation index and plasma viscosity were significantly higher in CSX patients.
- Increased erythrocyte aggregation and RDW, and decreased erythrocyte deformability were associated with CSX risk.
Conclusions:
- Hemorheological impairments, including altered erythrocyte aggregation and deformability, are significantly associated with Cardiac Syndrome X.
- These findings highlight the role of blood rheology in the pathophysiology of CSX.
Background:
Cardiac syndrome X (CSX) is often described as angina or angina-like chest pain with a normal coronary arteriogram, yet the underlying pathophysiological mechanisms have not been fully elucidated. The aim of the current study was to determine alterations in blood rheology (erythrocyte aggregation and deformability, plasma viscosity - PV) in patients with CSX.
Methods:
The study comprised 26 CSX patients (55.77 ± 12.33 years) and 37 age- and sex-matched (56.32 ± 11.98 years) healthy controls. Erythrocyte aggregation and deformability were measured by an ektacytometer and PV with a rotational viscometer.
Results:
Erythrocyte deformability measured at 1.69 and 3.00 Pa was lower in the CSX patients compared to the controls (p = .0001 and .017, respectively). Erythrocyte aggregation index (AI) (72.758 ± 7.65 vs. 66.483 ± 6.63, p = .002) and PV measured at a shear rate of 375 s-1 (1.932 ± 0.225 vs. 1.725 ± 0.331, p = .019) were significantly higher in patients with CSX. When AI, RDW and erythrocyte deformability measured at 1.69 Pa were evaluated together, it was observed that the increase in AI and RDW augments the risk of having CSX (OR: 1.2 and 2.65, respectively), while the rise in deformability decreases this risk (OR = 0.02).
Conclusions:
Hemorheological impairments are associated with CSX.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Cardiomyopathy IV: Restrictive Cardiomyopathy

